NOVELTY - Polymer (I), comprising a conjugated pi-backbone, and a first group and a second group attached to the pi-backbone, is new, where the pi-backbone comprises a plane of atoms, the first group has a first fixed height above the plane and the second group has a second fixed height below the plane, the sum of the first and second heights is at least about 4.5 Angstrom , and the polymer has a fluorine content of greater than 50% by mass.    USE - The polymer is useful in a device comprising organic light-emitting diode, organic field effect transistor, or a photovoltaic cell (all claimed). The polymer is useful for detection, imaging, and/or treatment of a disorder or disease in a subject and/or tissue, where the disease is cancer, preferably breast cancer. (I) is useful for determining the presence or absence of a bacteria, virus, and/or biomarker. No biological data given.    ADVANTAGE - The polymer can be used in further applications without purification. The polymer comprise pi-conjugated backbones, and are highly emissive. The polymer has enhanced properties, including solubility, quantum yield, electron affinity, stability in air, semiconducting properties, in solution or in solid state. The emulsion is stable.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a polymer (II) comprising a conjugated pi-backbone comprising a thienopyrazine group, where (II) has a fluorine content of greater than 50% by mass and a solubility in non-fluorous solvents of less than 0.01 mg/ml;    (2) a thin film comprising the polymer;    (3) the preparation of the polymer;    (4) an emulsion-Q1, comprising a non-fluorous continuous phase, a fluorous non-continuous phase, and the luminescent polymer substantially contained within the fluorous non-continuous phase, where the quantum yield of the luminescent polymer is greater than 60%;    (5) an emulsion-Q2, comprising a non-fluorous continuous phase and a fluorous non-continuous phase, where a fluorous/non-fluorous interface is present between the fluorous and the non-fluorous phase, and the luminescent polymer arranged at the interface, where the quantum yield of the luminescent polymer is greater than 60%;    (6) determining, treating, or imaging a condition and/or disease in a subject, comprising providing an emulsion, comprising a fluorous non-continuous phase, a non-fluorous continuous phase, at least one surfactant, at least one surface-altering moiety, and the polymer, where the polymer and the at least one surfactant is contained with the fluorous phase, administering the emulsion to the subject, and imaging at least a portion of the subject; and    (7) a composition for determining, treating, or imaging a condition and/or disease in a subject, comprising an emulsion comprising a fluorous discontinuous phase, a fluorescent entity associated with the fluorous discontinuous phase, and at least one targeting moiety, associated with the emulsion, for targeting a species in or on the tissue or subject.